GW 2580

Key Product Details

Product Description

GW 2580 is a potent and selective cFMS kinase inhibitor (IC₅₀ = 0.06 μM). Exhibits selectivity for cFMS kinase over 186 other kinases. Inhibits CSF-1-induced growth of rat monocytes in vitro. Also inhibits bone resorption in osteoclast cultures, as well as connective tissue and bone destruction in a rat adjuvant arthritis model. Suppresses M-NFS-60 tumor cell growth in mice. Orally bioavailable.

Product Specifications for GW 2580

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GW 2580

The following data is based on the product molecular weight 366.41.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.46 mL	27.29 mL	54.58 mL
2.5 mM	1.09 mL	5.46 mL	10.92 mL
5 mM	0.55 mL	2.73 mL	5.46 mL
25 mM	0.11 mL	0.55 mL	1.09 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Conway Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J.Pharmacol.Exp.Ther. 2008 PMID: 18434589
• Conway Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc.Natl.Acad.Sci.U.S.A. 2005 PMID: 16249345

Product Documents for GW 2580